An experimental Alzheimer's drug slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, potentially a rare win in a field littered with failed drugs.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Alzheimer’s Drug Slows Disease Progression in TrialEisai and Biogen said their experimental Alzheimer’s drug significantly slowed progression of the memory-robbing disease in a large study, bolstering the drug’s prospects of approval.
Baca lebih lajut »
Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer's drug successBiogen and partner Eisai late Tuesday reported positive results from a late stage, large trial of their experimental Alzheimer's drug.
Baca lebih lajut »
Alzheimer's drug slows progression of cognitive decline in clinical trial, drugmakers say | CNNA monoclonal antibody treatment for Alzheimer's disease called lecanemab slows the progression of cognitive decline by 27% compared with a placebo, drugmakers Biogen and Eisai said Tuesday.
Baca lebih lajut »
Experimental Alzheimer's drug shows benefits in phase 3 trial, company saysJapanese drugmaker Eisai said cognitive function slowed over 18 months in patients who received the drug, called lecanemab.
Baca lebih lajut »
Regulatory approval is next: Mizuho lifts Biogen to buy on news of Alzheimer's drug successBiogen and partner Eisai late Tuesday reported positive results from a late stage, large trial of their experimental Alzheimer's drug.
Baca lebih lajut »
Alzheimer’s Drug Slows Disease Progression in TrialEisai and Biogen said their experimental Alzheimer’s drug significantly slowed progression of the memory-robbing disease in a large study, bolstering the drug’s prospects of approval.
Baca lebih lajut »